Brief: Vaxart Initiates Dosing In 10,000-Participant Portion Of Phase 2B Covid-19 Trial
27/05/2025 13:46
May 27 (Reuters) - Vaxart Inc VXRT.O: VAXART INITIATES DOSING IN 10,000-PARTICIPANT PORTION OF PHASE 2B COVID-19 TRIAL Source text: ID:nGNX4s5QCq Further company coverage: VXRT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts